Prexasertib
Phase 2Small molecule
Eli LillyPrexasertib is one of 164 small molecule programs targeting Desmoplastic Small Round Cell Tumor. It is currently in Phase 2.
5
Indications
15
Total Trials
0
Active Trials
163
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Piqray
NovartisPhase 3
Bavencio
EMD SeronoPhase 3
SHR-A1811
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Defactinib
VVerastem, Inc.
Phase 3
H1 Receptor Antagonist
Merck & Co.Phase 3
Prexasertib
Eli LillyPhase 2
Gleolan
NNX Development Corp
Phase 3
HS-20089
HHansoh BioMedical R&D Company
Phase 3
Nemvaleukin
MMural Oncology, Inc
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Advanced Cancer3 trials
Patients With Advanced Solid Tumors2 trials
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT03057145·29 enrolled
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
Completed·—·Phase 1·NCT03495323·17 enrolled
Desmoplastic Small Round Cell Tumor1 trial
Metastatic Cancer1 trial
7 more indications
Relapsed/Refractory AML1 trial
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
Terminated·—·Phase 1·NCT03735446·2 enrolled
Recurrent or Refractory Solid Tumors1 trial
Advanced Cancers1 trial
Head and Neck Cancer1 trial
Small Cell Lung Cancer1 trial
Medulloblastoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Prexasertib. EMBL-EBI & Wellcome Sanger Institute.
- [4]